<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30278574</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>11</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>14</Day>        </DateRevised>        <Article PubModel="Print">            <Journal>                <ISSN IssnType="Electronic">1536-5964</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>97</Volume>                    <Issue>39</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                    </PubDate>                </JournalIssue>                <Title>Medicine</Title>                <ISOAbbreviation>Medicine (Baltimore)</ISOAbbreviation>            </Journal>            <ArticleTitle>Problems to affect long-term survival for breast cancer patients: An observational study of subsequent lung/bronchus malignancies.</ArticleTitle>            <Pagination>                <MedlinePgn>e12603</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1097/MD.0000000000012603</ELocationID>            <Abstract>                <AbstractText>The overall survival of breast cancer (BC) patients increased significantly for decades; however, their long-term survival was seriously impaired by subsequent malignancies. This study aimed to investigate the risk factors of subsequent lung / bronchus primary malignancies among BC survivors.A total of 535,941 BC female survivors diagnosed were identified by using SEERStat database in 1973 to 2014. Among them, 9398 had subsequent lung/bronchus malignancies. Clinico-pathological risk factors were evaluated for the development of subsequent lung/bronchus cancer. The main measures were the incidence and risk factors of subsequent lung/bronchus primaries. Logistic regression analysis and survival analysis were performed.Overall, among 535,941 BC survivors, 73,394 (13.69%) patients with subsequent primaries were identified from 1973 to 2014. The overall medium second tumor-free time was 72 months. Estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, human epidermal growth factor receptor-2 (HER2)-positive, radiotherapy, and surgery treatment were protective factors against overall subsequent malignancies, whereas HER2/hormone receptor (HR) subtype triple negative, increasing tumor size, low differentiation grade, and high TNM stage were risk factors associated with overall subsequent malignancies. Surgical implantation reconstruction was risk factor for lung/bronchus cancer. Even though BC patients had a favorite 5-year survival, their long-term survival was affected by subsequent malignancies, especially for lung/bronchus cancer with high mortality.Nearly 13% BC survivors suffered from subsequent malignancies. Increased risk was related to HER2/HR triple negative and advanced TNM stages. Radiotherapy and surgery were protective factors. Our findings may inform the subsequent cancer counseling of female BC survivors.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Liu</LastName>                    <ForeName>Jieqiong</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Xiangya Hospital, Central South University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hu</LastName>                    <ForeName>Zheyu</ForeName>                    <Initials>Z</Initials>                    <AffiliationInfo>                        <Affiliation>Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya, School of Medicine, Central South University, Changsha, People's Republic of China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Feng</LastName>                    <ForeName>Yuhua</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Xiangya Hospital, Central South University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zeng</LastName>                    <ForeName>Shan</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Xiangya Hospital, Central South University.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhong</LastName>                    <ForeName>Meizuo</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Xiangya Hospital, Central South University.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D064888">Observational Study</PublicationType>            </PublicationTypeList>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Medicine (Baltimore)</MedlineTA>            <NlmUniqueID>2985248R</NlmUniqueID>            <ISSNLinking>0025-7974</ISSNLinking>        </MedlineJournalInfo>        <CitationSubset>AIM</CitationSubset>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 1998 Mar;16(3):1008-12</RefSource>                <PMID Version="1">9508184</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2012 Oct;135(3):849-55</RefSource>                <PMID Version="1">22903686</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2008 Aug 23;372(9639):608-10</RefSource>                <PMID Version="1">18722851</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Mol Med (Berl). 2014 Aug;92(8):837-45</RefSource>                <PMID Version="1">24906457</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2007 Apr 19;356(16):1670-4</RefSource>                <PMID Version="1">17442911</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg Oncol. 2009 Apr;16(4):1033-8</RefSource>                <PMID Version="1">19190966</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2015 Mar;16(3):266-73</RefSource>                <PMID Version="1">25637340</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2008 Mar 1;122(5):1114-7</RefSource>                <PMID Version="1">17973260</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2001 Feb 15;19(4):1231-3</RefSource>                <PMID Version="1">11181691</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>EBioMedicine. 2018 Jun;32:111-118</RefSource>                <PMID Version="1">29807833</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2011 Nov-Dec;61(6):409-18</RefSource>                <PMID Version="1">21969133</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2006 Jan 25;295(4):387-8</RefSource>                <PMID Version="1">16434628</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):389-96</RefSource>                <PMID Version="1">21217087</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Leukemia. 2007 Jul;21(7):1413-22</RefSource>                <PMID Version="1">17476281</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diagn Pathol. 2009 Apr 02;4:11</RefSource>                <PMID Version="1">19341480</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann Surg Oncol. 2013 Aug;20(8):2746-53</RefSource>                <PMID Version="1">23504142</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2011 Aug 1;29(22):e661-3</RefSource>                <PMID Version="1">21646611</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2016 Sep;66(5):359-69</RefSource>                <PMID Version="1">27175568</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2003 Jun 1;21(11):2123-37</RefSource>                <PMID Version="1">12775738</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2016 Jun 28;115(1):80-4</RefSource>                <PMID Version="1">27187684</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Biol Ther. 2016;17(2):125-8</RefSource>                <PMID Version="1">26861804</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Lab. 2017 Jan 1;63(1):67-72</RefSource>                <PMID Version="1">28164497</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thorac Oncol. 2014 Aug;9(8):1081-90</RefSource>                <PMID Version="1">25157761</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2016 Jan-Feb;66(1):31-42</RefSource>                <PMID Version="1">26513636</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet Oncol. 2010 Dec;11(12):1184-92</RefSource>                <PMID Version="1">20541465</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2002 Jul 17;288(3):321-33</RefSource>                <PMID Version="1">12117397</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bull Cancer. 2010 Feb;97(2):245-54</RefSource>                <PMID Version="1">19819776</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2013 Apr;138(3):665-73</RefSource>                <PMID Version="1">23546552</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cancer. 2014 Jan 23;5(2):151-5</RefSource>                <PMID Version="1">24563669</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2012 Sep 1;18(17):4549-59</RefSource>                <PMID Version="1">22791880</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Lancet. 2011 Oct 22;378(9801):1461-84</RefSource>                <PMID Version="1">21924486</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2017 Jan 26;376(4):367</RefSource>                <PMID Version="1">28121510</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Br J Cancer. 2006 Aug 7;95(3):390-2</RefSource>                <PMID Version="1">16804519</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2014 Sep 11;33(37):4568-78</RefSource>                <PMID Version="1">24662831</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 1999 Oct 6;91(19):1654-62</RefSource>                <PMID Version="1">10511593</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2016 Jul;66(4):271-89</RefSource>                <PMID Version="1">27253694</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2005 Oct 27;353(17):1784-92</RefSource>                <PMID Version="1">16251534</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2014 Jul 20;32(21):2255-69</RefSource>                <PMID Version="1">24868023</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Breast Cancer. 2018 Oct;18(5):e1149-e1163</RefSource>                <PMID Version="1">29885789</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2004 Oct 1;101(7):1514-23</RefSource>                <PMID Version="1">15378473</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Thorac Oncol. 2017 May;12(5):782-790</RefSource>                <PMID Version="1">28214559</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2009 Sep 15;115(18):4055-63</RefSource>                <PMID Version="1">19526590</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Dermatol. 1999 Mar;9(2):118-21</RefSource>                <PMID Version="1">10066960</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Epidemiol. 2017 Jun;48:22-28</RefSource>                <PMID Version="1">28319725</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Acta Derm Venereol. 2010 May;90(3):283-6</RefSource>                <PMID Version="1">20526547</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>                <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001984" MajorTopicYN="N">Bronchial Neoplasms</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>                <QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018426" MajorTopicYN="N">SEER Program</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName>                <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>            </MeshHeading>        </MeshHeadingList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>4</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30278574</ArticleId>            <ArticleId IdType="doi">10.1097/MD.0000000000012603</ArticleId>            <ArticleId IdType="pii">00005792-201809280-00096</ArticleId>            <ArticleId IdType="pmc">PMC6181575</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>